Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ASCO: More is better

Product Development

ASCO: More is better

The jar of potential treatments for colorectal cancer received a good shake last week, with double-header presentations from Genentech Inc. and Merck KGaA showing positive results for Avastin bevacizumab and Erbitux cetuximab. Add in positive data for the approved Eloxatin oxaliplatin from Sanofi-Synthelabo S.A., and CRC patients are looking at more treatment options that increase their survival in the near term.

The data presented at the American Society of Clinical Oncology meeting in Chicago, especially the Avastin findings, broadened the treatment picture for the disease, which had been focused on the coming phalanx of epidermal growth factor receptor (EGFR) blockers, including Erbitux and Iressa gefitinib from AstraZeneca plc, Tarcva erlotanib from OSI Pharmaceuticals Inc., and the ABX-EGF

Read the full 1207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE